Profile for Canada Patent: 2967951
✉ Email this page to a colleague
US Patent Family Members and Approved Drugs for Canada Patent: 2967951
US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
---|---|---|---|---|
⤷ Sign Up | Nov 16, 2035 | Bayer Hlthcare | VITRAKVI | larotrectinib sulfate |
⤷ Sign Up | Nov 16, 2035 | Bayer Healthcare | VITRAKVI | larotrectinib sulfate |
⤷ Sign Up | Nov 16, 2035 | Bayer Hlthcare | VITRAKVI | larotrectinib sulfate |
⤷ Sign Up | Aug 15, 2036 | Bayer Hlthcare | VITRAKVI | larotrectinib sulfate |
⤷ Sign Up | Aug 15, 2036 | Bayer Healthcare | VITRAKVI | larotrectinib sulfate |
⤷ Sign Up | Nov 16, 2035 | Bayer Hlthcare | VITRAKVI | larotrectinib sulfate |
>US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |